糖尿病黄斑浮腫に対する硝子体内ベバシズマブ初回3回投与後の経過

Short-term outcome of three consecutive intravitreal injection of bevacizumab for diabetic macular edema

要約　目的：糖尿病黄斑浮腫に対し，導入期3回のベバシズマブ硝子体注射を行った短期結果の報告。対象と方法：糖尿病黄斑浮腫がある39例39眼を対象とした。平均年齢は65歳であった。ベバシズマブ硝子体注射を3回連続して行い，1か月後と2か月後の視力，中心窩網膜厚，微小視野計による網膜感度閾値を評価した。視力はlogMARで評価した。結果：視力，中心窩網膜厚，網膜感度閾値は，いずれも有意に改善した（p＜0.05）。2か月以降については，10眼（26％）では追加治療不要と判断され，15眼（38％）ではベバシズマブを維持投与し，14眼（36％）では他の加療が行われた。結論：導入期3回のベバシズマブ硝子体連続注射は，糖尿病黄斑浮腫に対し有効であった。2か月以降については，治療の継続または追加が必要な症例があった。

Abstract.　Purpose：To report 2-month outcome of three consecutive intravitreal injections of bevacizumab for diabetic macular edema. Cases and Method：This study was made on 39 eyes of 39 cases with diabetic macular edema. The age averaged 65 years. They received three consecutive intravitreal injection of bevacizumab. They were evaluated regarding visual acuity, foveal thickness, and threshold of retinal sensitivity one and two months after injection. Results：Visual acuity, foveal thickness and retinal sensitivity significantly improved 1 and 2 months after injection（p＜0.05）. After 2 months of injection, 10 eyes（26％）needed no further treatment, 15 eyes（38％）continued intravitreal injection of bevacizumab, and 14 eyes（36％）were switched to other therapeutic modalities. Conclusion：Three consecutive intravitreal injections of bevacizumab were generally effective for diabetic macular edema during the observation period of 2 months. After 2 months, there were cases who needed the same or other treatment.